Non Alcoholic Fatty Liver DiseaseNCT07768956
Effects of Turkish Coffee and Green Tea in Fatty Liver Disease
A study testing green tea, Turkish Coffee and mediterranean diet in people with Non Alcoholic Fatty Liver Disease, run by Okan University at 1 site in Turkey (Türkiye).
Trial summary
Non-alcoholic fatty liver disease (NAFLD) is a common liver condition associated with metabolic disorders and lifestyle factors. This study aims to evaluate the effects of Turkish coffee and green tea consumption in addition to a Mediterranean diet intervention on liver fat content, biochemical parameters, and… Read more about this study
- Who is it for?
- Ages 19 to 65 years
- Conditions the study is for
- Non Alcoholic Fatty Liver Disease
- What is being tested?
- green tea, Turkish Coffee and mediterranean diet
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 47 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 25 Sep 2024to 15 Aug 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Participants aged 19-65 years with a diagnosis of non-alcoholic fatty liver disease (NAFLD).
- Not using medications for diabetes, dyslipidemia, or rheumatoid arthritis.
- Not using dietary supplements.
- No dietary program followed within the previous month.
- No severe psychiatric disorders.
- Willingness to participate in the study and provide informed consent.
Who cannot join
- Presence of diabetes, dyslipidemia, or rheumatoid arthritis.
- Alcohol consumption.
- Positive hepatitis B surface antigen (HBsAg), hepatitis C positivity, autoimmune hepatitis, liver cirrhosis, toxic hepatitis, or alanine aminotransferase (ALT) levels ≥10 times the upper limit of normal.
- Presence of liver malignancy or hepatic decompensation.
- Use of systemic corticosteroids or methotrexate within the previous 6 months.
- Pregnancy or lactation.
Show all 10Show fewer
- Regular use of dietary supplements.
- Following a dietary program within the previous month.
- Presence of severe psychiatric disorders.
- High daily consumption of tea and coffee.
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Istanbul Dr. Lutfi Kirdar City Hospital
Istanbul, Istanbul, 34865
About this study
Official title: The Effects of Turkish Coffee and Green Tea Consumption on Liver Steatosis Level and Biochemical Parameters in Individuals With Non-Alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) is a common liver condition associated with metabolic disorders and lifestyle factors. This study aims to evaluate the effects of Turkish coffee and green tea consumption in addition to a Mediterranean diet intervention on liver fat content, biochemical parameters, and anthropometric measurements in individuals with fatty liver disease.
Participants received a 12-week Mediterranean diet program and were assigned to groups consuming Turkish coffee, green tea, or no additional beverage intervention. Changes in liver ultrasonography findings, liver enzymes, metabolic parameters, and body measurements were evaluated before and after the intervention.
Read the detailed description
Non-alcoholic fatty liver disease (NAFLD), recently included under the broader term metabolic dysfunction-associated steatotic liver disease (MASLD), is the most common chronic liver disease worldwide and is strongly associated with obesity, insulin resistance, and metabolic abnormalities. Lifestyle modification, particularly dietary interventions, is considered the cornerstone of NAFLD management.
This randomized controlled study was designed to investigate the effects of Turkish coffee and green tea consumption combined with a Mediterranean diet intervention on liver steatosis, biochemical parameters, and anthropometric measurements in individuals diagnosed with fatty liver disease.
Participants were assigned to three groups: a Turkish coffee group, a green tea group, and a control group. All participants received a 12-week Mediterranean diet intervention. In addition to the dietary intervention, the Turkish coffee group consumed Turkish coffee twice daily, while the green tea group consumed green tea three times daily. The control group continued with the Mediterranean diet without additional beverage intervention.
Before and after the 12-week intervention, participants were evaluated for liver steatosis using ultrasonography, liver function tests (including alanine aminotransferase [ALT], aspartate aminotransferase [AST], and gamma-glutamyl transferase [GGT]), metabolic parameters, and anthropometric measurements.
The aim of this study is to determine whether Turkish coffee and green tea consumption as an adjunct to a Mediterranean diet may have beneficial effects on liver fat accumulation and metabolic health parameters in individuals with fatty liver disease.
- Conditions
- Non Alcoholic Fatty Liver Disease
- Being tested
- green tea, Turkish Coffee, mediterranean diet
- Keywords
- non-alcoholic fatty liver disease, Turkish coffee, green tea, diet therapy
- Medical subject headings
- Non-alcoholic Fatty Liver Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
green teaBehavioural
Participants consumed green tea three times daily as an adjunct to a Mediterranean diet intervention for 12 weeks.
Turkish CoffeeBehavioural
Participants consumed Turkish coffee twice daily as an adjunct to a Mediterranean diet intervention for 12 weeks.
mediterranean dietBehavioural
participants received a Mediterranean diet intervention without additional Turkish coffee or green tea consumption for 12 weeks.
| Study group | Role | What they receive |
|---|---|---|
| Mediterranean Diet + Green Tea | Experimental | Participants received a Mediterranean diet intervention and consumed green tea three times daily as an adjunct to the diet for 12 weeks. Receives: Behavioral: green tea; Behavioral: mediterranean diet |
| Mediterranean Diet + Turkish Coffee | Experimental | Participants received a Mediterranean diet intervention and consumed Turkish coffee twice daily for 12 weeks Receives: Behavioral: Turkish Coffee; Behavioral: mediterranean diet |
| Mediterranean Diet Control | Active comparator | Participants received a Mediterranean diet intervention without additional Turkish coffee or green tea consumption for 12 weeks. Receives: Behavioral: mediterranean diet |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in liver steatozis grade by abdominal Ultrasonography
Liver steatosis was assessed by abdominal ultrasonography and graded as Grade 0 (no steatosis), Grade 1 (mild steatosis), Grade 2 (moderate steatosis), and Grade 3 (severe steatosis). Higher grades indicate greater severity of hepatic steatosis.
Measured: Baseline and 12 weeks
Secondary outcomes (3)
Change in Alanine Aminotransferase (ALT) Level (U/L)
Changes in serum alanine aminotransferase (ALT) (U/L) were measured at baseline and after 12 weeks intervention to evaluate changes in liver function.
Measured: Baseline and 12 Weeks
Change in Aspartate Aminotransferase (AST) Level (U/L)
Changes in serum aspartate aminotransferase (AST) levels (U/L) were measured at baseline and after the 12-week intervention.
Measured: Baseline and Week 12
Change in Gamma-Glutamyl Transferase (GGT) Level (U/L)
Changes in serum gamma-glutamyl transferase (GGT) levels (U/L) were measured at baseline and after the 12-week intervention.
Measured: Baseline and Week 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Aug 2026
- Study start25 Sep 2024
- Primary completion15 Aug 2025
- Study completion15 Aug 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Non Alcoholic Fatty Liver DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This is a 12-week, three-arm, parallel-group randomized controlled study. Participants were assigned to one of three groups: Turkish coffee group, green tea group, or control group. All participants received a Mediterranean diet intervention. In addition, the Turkish coffee group consumed Turkish coffee twice daily, and the green tea group consumed green tea three times daily. The control group received the Mediterranean diet intervention without additional beverage supplementation.
- Masking
- None (open label)
- Enrolment
- 47 participants (actual)
Sponsor and investigators
- Lead sponsor
- Okan University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Hande Öngün Yılmaz, PhD, Principal investigator, BANDIRMA ONYEDI EYLUL UNIVERSITY, BANDIRMA VOCATIONAL SCHOOL
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07768956
- Sponsor's protocol ID
- OKANU-NAFLD-2026-001
- Status last verified
- Jul 2026
- First submitted
- 4 Aug 2026
- Last updated
- 17 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effects of Turkish Coffee and Green Tea Consumption on Liver Steatosis Level and Biochemical Parameters in Individuals With Non-Alcoholic Fatty Liver Disease
- ClinicalTrials.gov ID
- NCT07768956
- Acronym / sponsor ID
- OKANU-NAFLD-2026-001
- Conditions
- Non Alcoholic Fatty Liver Disease
- Keywords
- non-alcoholic fatty liver disease, Turkish coffee, green tea, diet therapy
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 47 participants (actual)
- Lead sponsor
- Okan UniversityUniversity, hospital or other
- Study start
- 25 Sep 2024 (actual)
- Primary completion
- 15 Aug 2025 (actual)
- Study completion
- 15 Aug 2025 (actual)
- First posted
- 17 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Non-alcoholic fatty liver disease (NAFLD) is a common liver condition associated with metabolic disorders and lifestyle factors. This study aims to evaluate the effects of Turkish coffee and green tea consumption in addition to a Mediterranean diet intervention on liver fat content, biochemical parameters, and anthropometric measurements in individuals with fatty liver disease.
Participants received a 12-week Mediterranean diet program and were assigned to groups consuming Turkish coffee, green tea, or no additional beverage intervention. Changes in liver ultrasonography findings, liver enzymes, metabolic parameters, and body measurements were evaluated before and after the intervention.
Detailed description
Non-alcoholic fatty liver disease (NAFLD), recently included under the broader term metabolic dysfunction-associated steatotic liver disease (MASLD), is the most common chronic liver disease worldwide and is strongly associated with obesity, insulin resistance, and metabolic abnormalities. Lifestyle modification, particularly dietary interventions, is considered the cornerstone of NAFLD management.
This randomized controlled study was designed to investigate the effects of Turkish coffee and green tea consumption combined with a Mediterranean diet intervention on liver steatosis, biochemical parameters, and anthropometric measurements in individuals diagnosed with fatty liver disease.
Participants were assigned to three groups: a Turkish coffee group, a green tea group, and a control group. All participants received a 12-week Mediterranean diet intervention. In addition to the dietary intervention, the Turkish coffee group consumed Turkish coffee twice daily, while the green tea group consumed green tea three times daily. The control group continued with the Mediterranean diet without additional beverage intervention.
Before and after the 12-week intervention, participants were evaluated for liver steatosis using ultrasonography, liver function tests (including alanine aminotransferase [ALT], aspartate aminotransferase [AST], and gamma-glutamyl transferase [GGT]), metabolic parameters, and anthropometric measurements.
The aim of this study is to determine whether Turkish coffee and green tea consumption as an adjunct to a Mediterranean diet may have beneficial effects on liver fat accumulation and metabolic health parameters in individuals with fatty liver disease.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
- Model description
- This is a 12-week, three-arm, parallel-group randomized controlled study. Participants were assigned to one of three groups: Turkish coffee group, green tea group, or control group. All participants received a Mediterranean diet intervention. In addition, the Turkish coffee group consumed Turkish coffee twice daily, and the green tea group consumed green tea three times daily. The control group received the Mediterranean diet intervention without additional beverage supplementation.
| Arm | Type | Receives |
|---|---|---|
| Mediterranean Diet + Green Tea | Experimental | Behavioral: green tea, Behavioral: mediterranean dietParticipants received a Mediterranean diet intervention and consumed green tea three times daily as an adjunct to the diet for 12 weeks. |
| Mediterranean Diet + Turkish Coffee | Experimental | Behavioral: Turkish Coffee, Behavioral: mediterranean dietParticipants received a Mediterranean diet intervention and consumed Turkish coffee twice daily for 12 weeks |
| Mediterranean Diet Control | Active comparator | Behavioral: mediterranean dietParticipants received a Mediterranean diet intervention without additional Turkish coffee or green tea consumption for 12 weeks. |
Who may qualify
- Ages
- 19 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Participants aged 19-65 years with a diagnosis of non-alcoholic fatty liver disease (NAFLD).
- Not using medications for diabetes, dyslipidemia, or rheumatoid arthritis.
- Not using dietary supplements.
- No dietary program followed within the previous month.
- No severe psychiatric disorders.
Key exclusion criteria (10 listed)
- Presence of diabetes, dyslipidemia, or rheumatoid arthritis.
- Alcohol consumption.
- Positive hepatitis B surface antigen (HBsAg), hepatitis C positivity, autoimmune hepatitis, liver cirrhosis, toxic hepatitis, or alanine aminotransferase (ALT) levels ≥10 times the upper limit of normal.
- Presence of liver malignancy or hepatic decompensation.
- Use of systemic corticosteroids or methotrexate within the previous 6 months.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| green teaParticipants consumed green tea three times daily as an adjunct to a Mediterranean diet intervention for 12 weeks. | Behavioural | Mediterranean Diet + Green Tea |
| Turkish CoffeeParticipants consumed Turkish coffee twice daily as an adjunct to a Mediterranean diet intervention for 12 weeks. | Behavioural | Mediterranean Diet + Turkish Coffee |
| mediterranean dietparticipants received a Mediterranean diet intervention without additional Turkish coffee or green tea consumption for 12 weeks. | Behavioural | Mediterranean Diet + Green Tea, Mediterranean Diet + Turkish Coffee, Mediterranean Diet Control |
Primary outcome
Change in liver steatozis grade by abdominal Ultrasonography
Time frame: Baseline and 12 weeks
Liver steatosis was assessed by abdominal ultrasonography and graded as Grade 0 (no steatosis), Grade 1 (mild steatosis), Grade 2 (moderate steatosis), and Grade 3 (severe steatosis). Higher grades indicate greater severity of hepatic steatosis.
3 secondary outcomes
Change in Alanine Aminotransferase (ALT) Level (U/L)
Time frame: Baseline and 12 Weeks
Change in Aspartate Aminotransferase (AST) Level (U/L)
Time frame: Baseline and Week 12
Change in Gamma-Glutamyl Transferase (GGT) Level (U/L)
Time frame: Baseline and Week 12
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Aug 2026.
Related trials for Non Alcoholic Fatty Liver Disease
Not yet recruiting
Efficacy of Carnitine Complex in Improving Hepatic Steatosis in Potential Liver Donors
Hepatic Steatosis, Fatty Liver
Recruiting
NAFLD Clinical Care Pathway
NAFLD, MASLD
RecruitingPhase 3
Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD
RecruitingPhase 1
A Study of Efimosfermin Alfa in Adults With Hepatic Impairment
Non-alcoholic Fatty Liver Disease
RecruitingPhase 2
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
Metabolic Dysfunction-Associated Steatohepatitis, Non-alcoholic Fatty Liver Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Hande Öngün Yılmaz, PhD principal investigator
BANDIRMA ONYEDI EYLUL UNIVERSITY, BANDIRMA VOCATIONAL SCHOOL
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing green tea, Turkish Coffee and mediterranean diet in people with Non Alcoholic Fatty Liver Disease, run by Okan University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in liver steatozis grade by abdominal Ultrasonography (time frame: Baseline and 12 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Aug 2026.